Institutional members access full text with Ovid®

Share this article on:

Neoadjuvant Versus Adjuvant Systemic Therapy for Operable Breast Cancer: Equivalent Outcomes?

Smith, Barbara L. MD, PhD

doi: 10.1097/SLA.0b013e318280a688
Editorial

Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA.

Reprints: Barbara L. Smith, MD, PhD, Division of Surgical Oncology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114. E-mail: blsmith1@partners.org.

Disclosure: The author declares no conflicts of interest.

© 2013 Lippincott Williams & Wilkins, Inc.